First Time Loading...

4D Molecular Therapeutics Inc
NASDAQ:FDMT

Watchlist Manager
4D Molecular Therapeutics Inc Logo
4D Molecular Therapeutics Inc
NASDAQ:FDMT
Watchlist
Price: 26.38 USD 3.9% Market Closed
Updated: May 3, 2024
Section:
 

Wall Street
Price Targets

FDMT Price Targets Summary
4D Molecular Therapeutics Inc

Wall Street analysts forecast FDMT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FDMT is 53.24 USD with a low forecast of 34.34 USD and a high forecast of 86.1 USD.

FDMT Lowest Forecast
Wall Street Target
34.34 USD
30% Upside
FDMT Average Forecast
Wall Street Target
53.24 USD
102% Upside
FDMT Highest Forecast
Wall Street Target
86.1 USD
226% Upside
Lowest
Price Target
34.34 USD
30% Upside
Average
Price Target
53.24 USD
102% Upside
Highest
Price Target
86.1 USD
226% Upside

FDMT Last Price Targets
4D Molecular Therapeutics Inc

The latest public price target was made on Apr 15, 2024 by Gena Wang from Barclays , who expects FDMT stock to rise by 71% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Gena Wang
Barclays
45 USD
Upside 71%
2 weeks ago
Apr 15, 2024
Barclays Starts 4D Molecular Therapeutics (FDMT) at Overweight
StreetInsider
Lisa Walter
RBC Capital
40 USD
Upside 52%
2 weeks ago
Apr 15, 2024
4D Molecular Therapeutics (FDMT) PT Raised to $40 at RBC Capital
StreetInsider
Nalin Tejavibulya
Jefferies
58 USD
Upside 120%
1 month ago
Apr 1, 2024
4D Molecular Therapeutics (FDMT) PT Raised to $58 at Jefferies on multiple catalysts in 2024
StreetInsider
Kostas Biliouris
BMO Capital
63 USD
Upside 139%
1 month ago
Mar 28, 2024
4D Molecular Therapeutics (FDMT) PT Lowered to $63 at BMO Capital, 'uncertainty remains a lingering overhang until the PhIII readout'
StreetInsider
Kostas Biliouris
BMO Capital
70 USD
Upside 165%
2 months ago
Feb 6, 2024
4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast
Benzinga
Geulah Livshits
Chardan Capital
30 USD
Upside 14%
9 months ago
Jul 5, 2023
4D Molecular Poised For Success: FDA Discussion And Solid Position In Competitive Genetic Medicine Space, Says Analyst
Benzinga
Show More Price Targets
Show Less Price Targets
Gena Wang
Barclays
Price Target 45 USD
Upside/Downside 71%
View Source
Lisa Walter
RBC Capital
Price Target 40 USD
Upside/Downside 52%
View Source
Nalin Tejavibulya
Jefferies
Price Target 58 USD
Upside/Downside 120%
View Source
Kostas Biliouris
BMO Capital
Price Target 63 USD
Upside/Downside 139%
View Source
Kostas Biliouris
BMO Capital
Price Target 70 USD
Upside/Downside 165%
View Source
Geulah Livshits
Chardan Capital
Price Target 30 USD
Upside/Downside 14%
View Source
Show More Price Targets
Show Less Price Targets
4D Molecular Therapeutics Inc Competitors:
Price Targets
NBIX
Neurocrine Biosciences Inc
12% Upside
TGTX
TG Therapeutics Inc
89% Upside
ARWR
Arrowhead Pharmaceuticals Inc
134% Upside
APLT
Applied Therapeutics Inc
161% Upside
NBIX
Neurocrine Biosciences Inc
12% Upside
TGTX
TG Therapeutics Inc
89% Upside
ARWR
Arrowhead Pharmaceuticals Inc
134% Upside
APLT
Applied Therapeutics Inc
161% Upside
GILD
Gilead Sciences Inc
29% Upside
J
7774
Japan Tissue Engineering Co Ltd
92% Upside
GTH
Genetron Holdings Ltd
67% Downside
OPK
OPKO Health Inc
233% Upside

Revenue
Forecast

Revenue Estimate
4D Molecular Therapeutics Inc

For the last 5 years the compound annual growth rate for 4D Molecular Therapeutics Inc's revenue is 8%. The projected CAGR for the next 3 years is -54%.

8%
Past Growth
-54%
Estimated Growth
Estimates Accuracy
-11%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
4D Molecular Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
4D Molecular Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-40%
Average Miss
What are analyst estimates?

See Also

Summary
FDMT intrinsic value, competitors valuation, and company profile.
DCF Valuation
FDMT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
FDMT stock valuation using valuation multiples.
Wall Street Estimates
FDMT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
FDMT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is FDMT's stock price target?
Price Target
53.24 USD

According to Wall Street analysts, the average 1-year price target for FDMT is 53.24 USD with a low forecast of 34.34 USD and a high forecast of 86.1 USD.

What is 4D Molecular Therapeutics Inc's Revenue forecast?
Projected CAGR
-54%

For the last 5 years the compound annual growth rate for 4D Molecular Therapeutics Inc's revenue is 8%. The projected CAGR for the next 3 years is -54%.

ALPHA SPREAD
Join more than 133,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.